NEW YORK (GenomeWeb) – BioTime subsidiary OncoCyte has entered into a deal with Cornell University to collaborate on developing a lung cancer diagnostic test, the parties announced today.

As part of the deal, Weill Cornell Medical College will provide blood samples derived from healthy patients and lung cancer patients. OncoCyte researchers will then use the firm's PanC-Dx diagnostic tests to analyze the samples to determine levels of tumor-associated gene expression, including levels of the company's proprietary PanC-Dx cancer biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.